Literature DB >> 31482497

Key Physicochemical Characteristics Influencing ADME Properties of Therapeutic Proteins.

Xing Jing1, Yan Hou2, William Hallett2, Chandrahas G Sahajwalla2, Ping Ji2.   

Abstract

Therapeutic proteins are a rapidly growing class of drugs in clinical settings. The pharmacokinetics (PK) of therapeutic proteins relies on their absorption, distribution, metabolism, and excretion (ADME) properties. Moreover, the ADME properties of therapeutic proteins are impacted by their physicochemical characteristics. Comprehensive evaluation of these characteristics and their impact on ADME properties are critical to successful drug development. This chapter summarizes all relevant physicochemical characteristics and their effect on ADME properties of therapeutic proteins.

Entities:  

Keywords:  ADME; Pharmacokinetics (PK); Physicochemical characteristics; Protein therapeutics

Mesh：

Substances：

Year:  2019        PMID： 31482497     DOI： 10.1007/978-981-13-7709-9_6

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


  89 in total

1.  Insulin analogs with improved pharmacokinetic profiles.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1999-02-01       Impact factor: 15.470

Review 2.  Effects of charge on antibody tissue distribution and pharmacokinetics.

Authors:  C Andrew Boswell; Devin B Tesar; Kiran Mukhyala; Frank-Peter Theil; Paul J Fielder; Leslie A Khawli
Journal:  Bioconjug Chem       Date:  2010-11-05       Impact factor: 4.774

3.  Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies.

Authors:  Alain Beck; Janice M Reichert
Journal:  MAbs       Date:  2011-09-01       Impact factor: 5.857

Review 4.  Monomeric insulins and their experimental and clinical implications.

Authors:  J Brange; D R Owens; S Kang; A Vølund
Journal:  Diabetes Care       Date:  1990-09       Impact factor: 19.112

Review 5.  Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics.

Authors:  Daniela Bumbaca; C Andrew Boswell; Paul J Fielder; Leslie A Khawli
Journal:  AAPS J       Date:  2012-05-18       Impact factor: 4.009

Review 6.  Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates.

Authors:  Paolo Caliceti; Francesco M Veronese
Journal:  Adv Drug Deliv Rev       Date:  2003-09-26       Impact factor: 15.470

7.  Structural evidence suggests that antiactivator ExsD from Pseudomonas aeruginosa is a DNA binding protein.

Authors:  Robert C Bernhards; Xing Jing; Nancy J Vogelaar; Howard Robinson; Florian D Schubot
Journal:  Protein Sci       Date:  2009-03       Impact factor: 6.725

8.  In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells.

Authors:  G P Coffey; E Stefanich; S Palmieri; R Eckert; J Padilla-Eagar; P J Fielder; S Pippig
Journal:  J Pharmacol Exp Ther       Date:  2004-06-09       Impact factor: 4.030

9.  Monomeric insulins obtained by protein engineering and their medical implications.

Authors:  J Brange; U Ribel; J F Hansen; G Dodson; M T Hansen; S Havelund; S G Melberg; F Norris; K Norris; L Snel
Journal:  Nature       Date:  1988-06-16       Impact factor: 49.962

Review 10.  The emerging role of biotechnological drugs in the treatment of gout.

Authors:  L Cavagna; W J Taylor
Journal:  Biomed Res Int       Date:  2014-04-16       Impact factor: 3.411
View more
  1 in total

Review 1.  Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: lessons from the pandemic and preparing for future health crises.

Authors:  Natesh Singh; Bruno O Villoutreix
Journal:  Comput Struct Biotechnol J       Date:  2021-04-26       Impact factor: 7.271
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.